32 results about "Tissue diagnosis" patented technology

A portable mechanical high-precision device for performing circular or helical scanning of a patient's organ or body surface for tissue diagnosis and / or treatment includes a substantially hollow housing for accommodating the organ therein and a securing unit for securing the housing to the organ or body surface during scanning so that the organ or body surface is substantially fixed relative to the housing. At least one drive unit is attached to the housing and to at least one scan head for allowing unlimited rotation of the scan head relative to the housing.

Disclosed are methods for diagnosing breast cancer in a cell sample by detecting an increase in the levels of expression of protein markers in the cell sample as compared to the levels of expression of the same protein markers in a normal, nonneoplastic breast cell sample. Also disclosed is a device for diagnosis of cancer in a cell sample.

A device and method for safely securing a multilumen device to a tissue, organ or solid tumor within the body of a human during a diagnostic or therapeutic procedure is described. The device is capable of securing the tumor by touching or piercing its surface and providing a coolant to the distal tip. Cooling the tip forms a cryogenically induced region that tightly binds the tip to the tumor, temporarily sealing the entry-track of the instrument. The device further provides at least one injecting / aspirating lumen that can dispense or aspirate a fluid within the tumor, and an outer sheath or guide. Such construction allows injecting part or whole volume of the tumor while the cryogenically induced bond prevents back-flow of the injected substances through the entry-track.

The present disclosure relates to an apparatus and method for synthetically making an ultra-wide imaging bandwidth in millimeter-wave frequencies, resulting in improved image resolutions to values previously unattained. The synthetic approach sums up a number of available sub-bands (channels) to build an unavailable ultra-wideband system. Each channel contains an antenna unit which is optimized for operation within that specific sub-band. The number and position of the channels can be adjusted to cover any frequency range as required for the specific application.

The invention relates to the technical field of optical fiber sensing medical devices, in particular to an OCT imaging system for integrated optical fiber sensing in-vivo multi-parameter measurement.The OCT imaging system includes a light source module, a first coupler, a first annular device, an interference module, a special-shaped optical fiber microprobe, a photoelectric detector and a balance detector. Two output ports of the first coupler are connected with an input end of the interference module and a port A of the first annular device respectively; the special-shaped optical fiber microprobe is connected with an interference arm of the interference module and a port B of the first annular device through sector-shaped optical fiber bundles separately; the balance detector is connected with the interference module and a data processing module separately, and the photoelectric detector is connected with a port C of the first annular device and the data processing module separately. The OCT imaging system is reasonable in structure, the OCT probe is integrated with an FBG temperature sensing optical grating and an F-P pressure sensing unit, and the temperature, pressure and other parameters of body tissue are measured at the same time. Precise observation of the shape of the tissue and high-resolution large-scale imaging are achieved, and a significant meaning is achievedon in-vivo tissue diagnoses and the like.

Provided is a method of obtaining an index value used for pathological tissue diagnosis of prostate cancer, which method has low invasiveness and can be performed at a low cost. The method is a method of estimating a Gleason score that represents the malignancy of prostate cancer, which method includes: measuring the content of a prostate-specific antigen having an N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a sample; and estimating that the Gleason score is 7 or higher when the thus measured value is larger than a threshold value, or estimating that the Gleason score is 6 or lower when the measured value is smaller than a threshold value. The prostate-specific antigen is preferably quantified by a method including the step of binding a molecule having an affinity for β-N-acetylgalactosamine residue, such as Wisteria floribunda lectin, soybean agglutinin, Vicia Villosa lectin or an anti-β-N-acetylgalactosamine antibody, to the prostate-specific antigen.

The embodiments described herein relate to devices, systems and methods for in-vivo diagnosis of disease-state tissue within a body.